Most cited papers from St. Josef-Hospital

St. Josef-Hospital

What are the most cited papers from St. Josef-Hospital?

The most cited paper from St. Josef-Hospital is "Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes" (Steven P. Marso, Gilbert H. Daniels, Kirstine Brown‐Frandsen et al., 2016), with 7,629 citations. Next come "FSP1 is a glutathione-independent ferroptosis suppressor" (3,394) and "Glucagon-like peptide 1 (GLP-1)" (1,836).

Published TypeFieldAccessAuthorsCitations

Showing 50 of 61 papers. Every paper with more than 349 citations is listed.

Most cited papers, sortable by citations and release date
#	Paper
1	Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes Steven P. Marso, Gilbert H. Daniels, Kirstine Brown‐Frandsen et al. · New England Journal of Medicine Open access	13 Jun 2016	7,629
2	FSP1 is a glutathione-independent ferroptosis suppressor Sebastian G. Doll et al. · Nature Open access	21 Oct 2019	3,394
3	Glucagon-like peptide 1 (GLP-1) Timo D. Müller et al. · Molecular Metabolism Open access	30 Sep 2019	1,836
4	Placebo-Controlled Phase 3 Study of Oral BG-12 for Relapsing Multiple Sclerosis Ralf Gold, Ludwig Kappos, Douglas Lorne Arnold et al. · New England Journal of Medicine Open access	19 Sep 2012	1,735
5	GLP-1 receptor agonists in the treatment of type 2 diabetes – state-of-the-art Michael Albrecht Nauck, Daniel Robert Quast, Jakob Wefers et al. · Molecular Metabolism Open access	14 Oct 2020	1,616
6	Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6) John B. Buse, Julio Rosenstock, Giorgio Sesti et al. · The Lancet	9 Jun 2009	1,505
7	Spatial and temporal heterogeneity of mouse and human microglia at single-cell resolution Takahiro Masuda, Roman Sankowski, Ori Staszewski et al. · Nature Open access	Feb 2019	1,388
8	GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus Juris Jendrik Meier · Nature Reviews Endocrinology Review	4 Sep 2012	1,313
9	Fumaric acid esters exert neuroprotective effects in neuroinflammation via activation of the Nrf2 antioxidant pathway Ralf Andreas Linker, De-Hyung Lee, Sarah T. Ryan et al. · Brain	22 Feb 2011	1,197
10	The EFSUMB Guidelines and Recommendations on the Clinical Practice of Contrast Enhanced Ultrasound (CEUS): Update 2011 on non-hepatic applications Fabio Piscaglia et al. · Ultraschall in der Medizin - European Journal of Ultrasound Open access	26 Aug 2011	1,085
11	Autosomal dominant cerebellar ataxias: clinical features, genetics, and pathogenesis Ludger J. Schöls, Peter O. Bauer, Thorsten Schmidt et al. · The Lancet Neurology	21 Apr 2004	1,078
12	COVID-19 and diabetes mellitus: from pathophysiology to clinical management Soo Lim, Jae Hyun Bae, Hyuk‐Sang Kwon et al. · Nature Reviews Endocrinology ReviewOpen access	13 Nov 2020	1,045
13	Detection of intracellular cytokines by flow cytometry Thomas Jung, Uwe Schauer, Christoph Heusser et al. · Journal of Immunological Methods	Feb 1993	990
14	Long-term effect of aspirin on cancer risk in carriers of hereditary colorectal cancer: an analysis from the CAPP2 randomised controlled trial John Burn et al. · The Lancet Open access	28 Oct 2011	959
15	Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study Ludwig Kappos et al. · The Lancet 328 authors	Mar 2018	944
16	Incretin hormones: Their role in health and disease Michael Albrecht Nauck, Juris Jendrik Meier · Diabetes Obesity and Metabolism	24 Jan 2018	938
17	Frequency and Spectrum of Cancers in the Peutz-Jeghers Syndrome Nicholas Hearle et al. · Clinical Cancer Research	15 May 2006	861
18	Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial Juan P. Frías, Michael Albrecht Nauck, Joanna T Van et al. · The Lancet	4 Oct 2018	819
19	Interleukin-1β and interleukin-6 are elevated in the cerebrospinal fluid of Alzheimer's and de novo Parkinson's disease patients Doris Blum-Degena, Thomas H. Müller, Wilfried Kuhn et al. · Neuroscience Letters	Dec 1995	806
20	Contrasting disease patterns in seropositive and seronegative neuromyelitis optica: A multicentre study of 175 patients Sven Jarius et al. · Journal of Neuroinflammation Open access	19 Jan 2012	773
21	ECTRIMS/EAN Guideline on the pharmacological treatment of people with multiple sclerosis Xavier Montalbán et al. · Multiple Sclerosis Journal Open access	20 Jan 2018	721
22	Altered Brain Metabolism of Iron as a Cause of Neurodegenerative Diseases? M. Gerlach, Dorit Ben‐Shachar, Peter Franz Riederer et al. · Journal of Neurochemistry	Sep 1994	709
23	Neural structures associated with recognition of facial expressions of basic emotions Reiner Sprengelmeyer, Martin Rausch, Ulf Theodor Eysel et al. · Proceedings of the Royal Society B Biological Sciences Open access	22 Oct 1998	673
24	Trial of Satralizumab in Neuromyelitis Optica Spectrum Disorder Takashi Yamamura, Ingo Kleiter, Kazuo Fujihara et al. · New England Journal of Medicine Open access	27 Nov 2019	667
25	Propionic Acid Shapes the Multiple Sclerosis Disease Course by an Immunomodulatory Mechanism Alexander Duscha et al. · Cell Open access	Mar 2020	655
26	Contemporary Presentation and Management of Valvular Heart Disease Bernard Iung et al. · Circulation Open access	12 Sep 2019	613
27	Update on the diagnosis and treatment of neuromyelitis optica: Recommendations of the Neuromyelitis Optica Study Group (NEMOS) Neuromyelitis Optica Study Group (NEMOS), Corinna Trebst, Sven Jarius et al. · Journal of Neurology Open access	22 Nov 2013	605
28	Oral semaglutide versus subcutaneous liraglutide and placebo in type 2 diabetes (PIONEER 4): a randomised, double-blind, phase 3a trial Richard E. Pratley, Aslam Amod, Soren Tetens Hoff et al. · The Lancet	8 Jun 2019	602
29	Cardiovascular Actions and Clinical Outcomes With Glucagon-Like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors Michael Albrecht Nauck, Juris Jendrik Meier, Matthew Aaron Cavender et al. · Circulation Open access	28 Aug 2017	589
30	Efficacy of stapler versus hand-sewn closure after distal pancreatectomy (DISPACT): a randomised, controlled multicentre trial Markus K. Diener et al. · The Lancet	Apr 2011	561
31	Sex and gender issues in multiple sclerosis Hanne Flinstad Harbo, Ralf Gold, Mar Tintoré · Therapeutic Advances in Neurological Disorders Open access	13 May 2013	533
32	Senataxin, the ortholog of a yeast RNA helicase, is mutant in ataxia-ocular apraxia 2 Maria-Ceù Moreira et al. · Nature Genetics Open access	8 Feb 2004	523
33	Extended Treatment Duration for Hepatitis C Virus Type 1: Comparing 48 Versus 72 Weeks of Peginterferon-Alfa-2a Plus Ribavirin Thomas Berg, Michael Wagner, Samer Nasser et al. · Gastroenterology Open access	Apr 2006	518
34	Induction of a non-encephalitogenic type 2 T helper-cell autoimmune response in multiple sclerosis after administration of an altered peptide ligand in a placebo-controlled, randomized phase II trial Ludwig Kappos et al. · Nature Medicine	Oct 2000	516
35	The management of intra-abdominal infections from a global perspective: 2017 WSES guidelines for management of intra-abdominal infections Massimo Sartelli et al. · World Journal of Emergency Surgery Open access	10 Jul 2017	504
36	The incretin effect in healthy individuals and those with type 2 diabetes: physiology, pathophysiology, and response to therapeutic interventions Michael Albrecht Nauck, Juris Jendrik Meier · The Lancet Diabetes & Endocrinology	14 Feb 2016	498
37	Efficacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study Ludwig Kappos, Ralf Gold, David H. Miller et al. · The Lancet Open access	Oct 2008	483
38	Progressive multiple sclerosis: from pathophysiology to therapeutic strategies Simon Faissner, Jason R. Plemel, Ralf Gold et al. · Nature Reviews Drug Discovery Review	9 Aug 2019	472
39	Secretion of glucagon-like peptide-1 (GLP-1) in type 2 diabetes: what is up, what is down? Michael Albrecht Nauck, Irfan Vardarli, Carolyn Fiona Deacon et al. · Diabetologia Open access	24 Sep 2010	464
40	Targeting Huntingtin Expression in Patients with Huntington's Disease Sarah J Tabrizi et al. · UCL Discovery (University College London)	2019	459
41	Consensus Report: Definition and Interpretation of Remission in Type 2 Diabetes Matthew C. Riddle, William T. Cefalu, Philip H. Evans et al. · Diabetes Care Open access	30 Aug 2021	442
42	Neuromyelitis optica: Evaluation of 871 attacks and 1,153 treatment courses Ingo Kleiter et al. · Annals of Neurology	4 Nov 2015	442
43	Incretin therapies: highlighting common features and differences in the modes of action of glucagon‐like peptide‐1 receptor agonists and dipeptidyl peptidase‐4 inhibitors Michael Albrecht Nauck · Diabetes Obesity and Metabolism Open access	22 Oct 2015	434
44	Cancer prevention with aspirin in hereditary colorectal cancer (Lynch syndrome), 10-year follow-up and registry-based 20-year data in the CAPP2 study: a double-blind, randomised, placebo-controlled trial John Burn et al. · The Lancet Open access	Jun 2020	431
45	Diagnosis of multiple sclerosis: 2024 revisions of the McDonald criteria Xavier Montalbán et al. · The Lancet Neurology Open access	17 Sep 2025	420
46	A Comparison of Surgical and Medical Therapy for Atrial Septal Defect in Adults Stavros Konstantinides, Annette Geibel, Manfred Olschewski et al. · New England Journal of Medicine Open access	24 Aug 1995	414
47	Management of acute pancreatitis: from surgery to interventional intensive care Jens Werner, S Feuerbach, W Uhl et al. · Gut Open access	11 Feb 2005	410
48	Degradation of Endogenous and Exogenous Gastric Inhibitory Polypeptide in Healthy and in Type 2 Diabetic Subjects as Revealed Using a New Assay for the Intact Peptide1 Carolyn Fiona Deacon, Michael Albrecht Nauck, Juris Jendrik Meier et al. · The Journal of Clinical Endocrinology & Metabolism Open access	Oct 2000	401
49	Tirzepatide, a dual GIP/GLP-1 receptor co-agonist for the treatment of type 2 diabetes with unmatched effectiveness regrading glycaemic control and body weight reduction Michael Albrecht Nauck, David A. D‘Alessio · Cardiovascular Diabetology Open access	Sep 2022	394
50	TNF receptor 1 genetic risk mirrors outcome of anti-TNF therapy in multiple sclerosis Adam Gregory et al. · Nature Open access	6 Jul 2012	390

Citations are OpenAlex's own counts, from its 2026-09-23 snapshot, so the ranking can differ from Google Scholar or Web of Science. A paper is listed for an institution when any of its authors gave it as an affiliation; retracted papers and papers whose citation count cannot be traced to citing works are left out, and a preprint and the article it became are shown once. Release dates are OpenAlex's: where a source gave only a month or a year, that is what is shown. How the lists are chosen.